Literature DB >> 12210929

Eliminating spurious lipid sidebands in 1H MRS of breast lesions.

Patrick J Bolan1, Lance DelaBarre, Eva H Baker, Hellmut Merkle, Lenore I Everson, Douglas Yee, Michael Garwood.   

Abstract

Detecting metabolites in breast lesions by in vivo (1)H MR spectroscopy can be difficult due to the abundance of mobile lipids in the breast which can produce spurious sidebands that interfere with the metabolite signals. Two-dimensional J-resolved spectroscopy has been demonstrated in the brain as a means to eliminate these artifacts from a large water signal; coherent sidebands are resolved at their natural frequencies, leaving the noncoupled metabolite resonances in the zero-frequency trace of the 2D spectrum. This work demonstrates that using the zero-frequency trace-or equivalently the average of spectra acquired with different echo times-can be used to separate noncoupled metabolite signals from the lipid-induced sidebands. This technique is demonstrated with simulations, phantom studies, and in several breast lesions. Compared to the conventional approach using a single echo time, echo time averaging provides increased sensitivity for the study of small and irregularly shaped lesions. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210929     DOI: 10.1002/mrm.10224

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  26 in total

1.  Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results.

Authors:  X Yao; M Zeng; H Wang; S Fei; S Rao; Y Ji
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

2.  (1)H MR spectroscopy with external reference solution at 1.5 T for differentiating malignant and benign breast lesions: comparison using qualitative and quantitative approaches.

Authors:  Waka Mizukoshi; Eito Kozawa; Kaiji Inoue; Naoko Saito; Naoko Nishi; Toshiaki Saeki; Fumiko Kimura
Journal:  Eur Radiol       Date:  2012-07-10       Impact factor: 5.315

3.  MR Spectroscopy in the diagnosis and treatment of breast cancer.

Authors:  Michael T Nelson; Lenore I Everson; Michael Garwood; Tim Emory; Patrick J Bolan
Journal:  Semin Breast Dis       Date:  2008-06-01

Review 4.  Metabolite quantification and high-field MRS in breast cancer.

Authors:  Ihab S Haddadin; Adeka McIntosh; Sina Meisamy; Curt Corum; Angela L Styczynski Snyder; Nathaniel J Powell; Michael T Nelson; Douglas Yee; Michael Garwood; Patrick J Bolan
Journal:  NMR Biomed       Date:  2009-01       Impact factor: 4.044

5.  Compensation of gradient-induced magnetic field perturbations.

Authors:  Terence W Nixon; Scott McIntyre; Douglas L Rothman; Robin A de Graaf
Journal:  J Magn Reson       Date:  2008-02-23       Impact factor: 2.229

6.  Fast multivoxel two-dimensional spectroscopic imaging at 3 T.

Authors:  Dong-Hyun Kim; Roland Henry; Daniel M Spielman
Journal:  Magn Reson Imaging       Date:  2007-04-05       Impact factor: 2.546

Review 7.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 8.  Glutamate and glutamine: a review of in vivo MRS in the human brain.

Authors:  Saadallah Ramadan; Alexander Lin; Peter Stanwell
Journal:  NMR Biomed       Date:  2013-10-04       Impact factor: 4.044

9.  Feasibility of single-voxel MRS measurement of apparent diffusion coefficient of water in breast tumors.

Authors:  C A Corum; A D McIntosh; P J Bolan; M Nelson; A L Snyder; N J Powell; J Boyum; T H Emory; D Yee; T M Tuttle; L I Everson; M Garwood
Journal:  Magn Reson Med       Date:  2009-05       Impact factor: 4.668

10.  Comparison of T(1) and T(2) metabolite relaxation times in glioma and normal brain at 3T.

Authors:  Yan Li; Radhika Srinivasan; Helene Ratiney; Ying Lu; Susan M Chang; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2008-08       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.